Endocrinol Metab.  2025 Feb;40(1):67-69. 10.3803/EnM.2025.2329.

Highlights of the Most Recent American Diabetes Association Guidelines: From Evidence to Practice

• Kim MK

• KMID: 2565253
• DOI: http://doi.org/10.3803/EnM.2025.2329

Figure

• 

  Fig. 1. The algorithm outlines two main pathways for managing type 2 diabetes mellitus. The pathway shown on the left focuses on mitigating cardiovascular and kidney risks, particularly in high-risk patients, while the pathway shown on the right emphasizes achieving and maintaining glycemic and weight management goals. Only drugs with very high efficacy for weight loss (e.g., semaglutide, tirzepatide) and glycemic control (e.g., dulaglutide [high dose], semaglutide, tirzepatide, and combination therapies with insulin and glucagon-like peptide-1 receptor agonists [GLP-1 RAs]) are highlighted to support reaching these targets. Additional considerations include the use of glucose-lowering agents for specific comorbidities, such as metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunctionassociated steatohepatitis (MASH). Modified from American Diabetes Association Professional Practice Committee [1], with permission from American Diabetes Association. HF, heart failure; CKD, chronic kidney disease; CVD, cardiovascular disease; SGLT2i, sodium-glucose cotransporter 2 inhibitor; HbA1c, hemoglobin A1c; CV, cardiovascular; GIP, glucose-dependent insulinotropic polypeptide; CGM, continuous glucose monitoring.

Reference

1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025; 48(Supplement 1):S181–206.

2. American Diabetes Association Professional Practice Committee. Erratum. 7. Diabetes technology: standards of care in diabetes-2025. Diabetes Care. 2025; 48(Suppl 1):S146–66.

3. American Diabetes Association Professional Practice Committee. Summary of revisions: standards of care in diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1):S6–13.

4. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389:1069–84.

5. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021; 384:1113–24.

6. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024; 391:299–310.

7. Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021; 131:e146353.

8. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81:492–542.

9. Silva Junior WS, Sposito AC, Godoy-Matos A. Should the new EASL-EASD-EASO clinical practice guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy? J Hepatol. 2025; 82:e21–2.

10. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42:1593–603.

11. Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013; 36:2009–14.